MarketCap
Facebook
X
Telegram
Rubius Therapeutics Balance Sheet 2022-2011 | RUBY
Brief overview of Rubius Therapeutics's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2018 and 2022.
Assets fell from $479.1 million to $23.1 million. This may reflect either deliberate optimization or a reduction in business scale.
Asset and liability trends were close, at -95.2% and -90.8%. Expansion did not materially reshape funding sources.
Internal capital represents 65.6% of the balance sheet, previously 82%. This is a strong capital position.
The cash share moved from 64.1% to 64.4%. A higher figure generally provides more room in an adverse scenario.
The balance sheet includes a negative accumulated result of -$856.7 million. It should be assessed alongside historical profits and capital distributions.
Balance sheet takeaway
Rubius Therapeutics's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Rubius Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -141 M | -7.28 M | -31.8 M | -283 M | -101 M | -4.08 M | - | - | - | - | - |
Long Term Debt |
- | 76.2 M | 74.9 M | 49.6 M | 24.3 M | 3.3 M | 2.99 M | - | - | - | - | - |
Long Term Debt Current |
1.1 M | 9.02 M | 8.94 M | 10.5 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 86.9 M | 66.1 M | 144 M | 22.3 M | - | - | - | - | - |
Total Current Liabilities |
7.94 M | 34.7 M | 27.8 M | 33.8 M | 20 M | 7.16 M | - | - | - | - | - | - |
Total Liabilities |
7.94 M | 139 M | 136 M | 121 M | 86.1 M | 11.6 M | 25.1 M | - | - | - | - | - |
Retained Earnings |
-857 M | -677 M | -480 M | -313 M | -150 M | -61 M | -17.1 M | - | - | - | - | - |
Total Assets |
23.1 M | 318 M | 278 M | 395 M | 479 M | 108 M | 7.99 M | - | - | - | - | - |
Cash and Cash Equivalents |
14.9 M | 226 M | 91.2 M | 91.9 M | 307 M | 104 M | 7.07 M | - | - | - | - | - |
Book Value |
15.1 M | 179 M | 142 M | 274 M | 393 M | 96.1 M | -17.1 M | - | - | - | - | - |
Total Shareholders Equity |
15.1 M | 179 M | 142 M | 274 M | 393 M | -43.7 M | -17.1 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Rubius Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 76.8 M | 76.6 M | 76.4 M | 76.2 M | 75.9 M | 75.7 M | 66.3 M | 74.9 M | 74.8 M | 74.7 M | 49.7 M | 49.6 M | 49.5 M | 49.4 M | 24.4 M | 24.3 M | 4.24 M | 5.16 M | 24.3 M | 3.3 M | 3.3 M | 3.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 134 M | 134 M | 132 M | 139 M | 137 M | 132 M | 129 M | 136 M | 139 M | 139 M | 113 M | 121 M | 125 M | 94.4 M | 69.8 M | 86.1 M | 41.8 M | 37.5 M | 86.1 M | 11.6 M | 11.6 M | 11.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -837 M | -774 M | -729 M | -677 M | -622 M | -573 M | -523 M | -480 M | -440 M | -399 M | -361 M | -313 M | -268 M | -221 M | -182 M | -150 M | -123 M | -105 M | -150 M | -61 M | -61 M | -61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | 171 M | 229 M | 267 M | 318 M | 361 M | 396 M | 430 M | 278 M | 312 M | 344 M | 348 M | 395 M | 432 M | 438 M | 441 M | 479 M | 453 M | 208 M | 479 M | 108 M | 108 M | 108 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | 104 M | 62.2 M | 98.1 M | 226 M | 264 M | 283 M | 288 M | 92.9 M | 75.2 M | 129 M | 145 M | 91.9 M | 110 M | 141 M | 192 M | 307 M | 355 M | 117 M | 307 M | 104 M | 104 M | 104 M | - | 7.07 M | - | - | - | 1.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | 36.6 M | 95.5 M | 135 M | 179 M | 224 M | 264 M | 301 M | 142 M | 173 M | 205 M | 235 M | 274 M | 307 M | 344 M | 372 M | 393 M | 411 M | 170 M | 393 M | 96.1 M | 96.1 M | 96.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | 36.6 M | 95.5 M | 135 M | 179 M | 224 M | 264 M | 301 M | 142 M | 173 M | 205 M | 235 M | 274 M | 307 M | 344 M | 372 M | 393 M | 411 M | -70.7 M | 393 M | -43.7 M | -43.7 M | -43.7 M | - | -17.1 M | - | - | - | -5.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Rubius Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
